


## Integrin $\beta 1$

**Catalogue no.:** Q75  
**Clone name:** FSH-14F8  
**Product:** VHH directed against Integrin  $\beta 1$

**Target:** Integrin  $\beta 1$  (ITGB1 or CD29, UniProtKB [P05556](#)) is one of the subunits belonging to the family of integrins, heterodimeric cell surface receptors that play a pivotal role in cell adhesion, migration, growth and survival.<sup>1,2</sup> The integrin family contains 18  $\alpha$ - and 8  $\beta$ -subunits that can form 24 different integrin heterodimers.<sup>3,4</sup> Via cooperation with other types of cell surface receptors (e.g. growth factor or G-protein coupled receptors), integrins can regulate intracellular signaling.<sup>5</sup> Integrin beta-1 is the most abundant  $\beta$ -integrin forms dimers with at least 10 different alpha subunits to form for example the Very Late Antigens VLA-3 ( $\alpha 3\beta 1$  integrin) and VLA-4 ( $\alpha 4\beta 1$  integrin).<sup>5</sup> Integrin  $\beta 1$  is also found overexpressed in various types of cancer.<sup>6</sup>



**Source:** Recombinant monoclonal VHH (*Llama glama*), purified from *S.cerevisiae* using affinity chromatography. Immunization with cells. Phage-display selection on captured recombinant antigen with total elution<sup>5</sup>.

**Specificity:** Human Integrin  $\beta 1$ .

**Formulation:** 0.2  $\mu$ m filtered solution in PBS.

**Storage:** Shipped on blue ice. Store at 4°C or -20°C (aliquots). Addition of 0.02% sodiumazide is optional.

**Applications:** ELISA, IF

### Products:

Cat. No.	Target	Tag	Label
Q75	Integrin $\beta 1$	Tagless	No label
Q75c	Integrin $\beta 1$	C-direct	No label
Q75c-lab	Integrin $\beta 1$	C-direct	Biotin / NOTA / HiLyte488 / IRDye800CW

### References:

- [Liu, S. et al.](#) (2000) J Cell Sci 113:3563-71
- [Hood, J.D. and Cheresh, D.A.](#) (2002) Nat Rev Cancer 2:91-100
- [Hynes, R.O.](#) (1992) Cell 69:11-25
- [van der Flier, A. and Sonnenberg, A.](#) (2001) Cell Tissue Res 305:285-298
- [Ramovs, V. et al.](#) (2017) Matrix Biol 57-58:213-243
- [Sun, Q. et al.](#) (2018) Onco Targets Ther 11:1787-1799